Johnson & Johnson (JNJ): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Johnson & Johnson ( JNJ) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Johnson & Johnson rose $1.47 (1.7%) to $88.75 on average volume. Throughout the day, 9,930,732 shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7,982,300 shares. The stock ranged in a price between $87.55-$88.76 after having opened the day at $87.63 as compared to the previous trading day's close of $87.28. Other companies within the Drugs industry that increased today were: Prima Biomed ( PBMD), up 45.3%, Repros Therapeutics ( RPRX), up 15.8%, Reliv' International ( RELV), up 11.1% and Can Fite Biofarma ( CANF), up 10.2%.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $244.4 billion and is part of the health care sector. Shares are down 4.7% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Oramed Pharmaceuticals ( ORMP), down 13.8%, DARA Biosciences ( DARA), down 13.8%, GW Pharmaceuticals ( GWPH), down 9.4% and Pernix Therapeutics Holdings ( PTX), down 9.3% , were all laggards within the drugs industry with Perrigo Company ( PRGO) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Micron Spikes After $10 Billion Buyback Plan Caps Bullish Q3 Earnings Forecast

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

Oil Prices, China Tariffs, Micron and Kohl's - 5 Things You Must Know

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China to Slash Automobile Tariffs and 4 Other Stories You Must Know Tuesday

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment

Global Stocks Push Higher as China Tariff Move, Softer US Dollar Boost Sentiment